Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cell And Gene Therapy Outcomes-Based Contracts In Medicaid Need ‘National’ Support,' HHS Says

Executive Summary

The demonstration project planned by the US Centers for Medicare and Medicaid Services is in keeping with past agency efforts to promote value-based contracts for cell and gene therapy.

You may also be interested in...



CMS Wants To Help With Medicaid Outcomes-Based Reimbursement For Cell And Gene Therapy

Center for Medicare and Medicaid Innovation (CMMI) deputy director Ellen Lukens talked about the goals and challenges of a new voluntary program the agency will test with state Medicaid programs.

Medicaid Outcomes-Based Payment Model For Cell, Gene Therapy to Launch In 2025

But CMMI does not yet have a launch date for the proposed Medicare demonstration on drugs cleared through FDA’s accelerated approval pathway and the demonstration allowing Part D plans to offer certain high-value generics with a $2 beneficiary copay.

Medicare, Medicaid Drug Payment Models Get Designated Team At CMMI

CMS’ innovation center creates new division to test alternative payment models, including likely new approaches for accelerated approval drugs and multi-state outcomes-based payment arrangements for cell and gene therapy in Medicaid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel